Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« Five Neurodevice Startups Target the Brain | Main | Neurotech Leaders Forum 2005 Conference Review »

October 23, 2005

Cutting Edge Neurodevice Technologies - MCS and TMS

Email This Entry

Posted by Zack Lynch

Warren Grill highlighted two areas:

-Motor Cortex Stimulation (MCS) to treat Parkinson's is showing promise in animal models. MCS normalizes rate and pattern of basal ganglia neurons in primates. This week in Neurosurgery an article showed that stimulation appeared to reduce amount of L-Dopa needed.

-TMS (transcranial magnetic stimulation) for migraine headache from Neuralieve looks interesting. The concept is that prior to onset of a migraine a lot of people get an aura, so when people get this feeling that stimulate their cortex with 2 pulses, 5 seconds apart. Neuralieve was founded by the same people who founded NeuroPace.

John Mcdonald, Director of the Spinal Cord Injury Institute spoke about Restorative Therapies' Activity Based Restoration program.

MindCare Centres opended first rTMS clinics for depression. What is rTMS? Repetitive Transcranial Magnetic Stimulation is a computer controlled magnetic beam applied 20 minutes a day that is non-invasive with minimal/or no side effects. No accidental seizures since 1996. rTMS may apply to many treatment resistant patients in the following markets: depression, anxiety, PTSD, OCD, tinnitus, pain, Parkinson's, migraines, aphasia, stroke (right after event), eating disorders, addiction.

Comments (1) + TrackBacks (0) | Category: Neurodevices


COMMENTS

1. Mike Flacklestein on June 16, 2006 9:13 PM writes...

I live at 34355 Commonwealth in Seattle. Been up here before?

Permalink to Comment

POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)





Remember me?


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
NIO Unveils Top 10 Neuroscience Trends for 2009
NIO CEO Media Tour in NYC Gets Results
O Neurocaster
Manuscript Sent to Japan
2009 Stem Cell Trendsetters in Neurology and Psychiatry
Mental Health Parity Legislation Passes within Financial Package
Holy Neurofinancial Meltdown Bernanke
Interest in Neuropolicy Grows